AHA 2019: Empagliflozin on Erythropoietin Levels – Dr David Mazer





The interactive transcript could not be loaded.


Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Dec 13, 2019

Dr David Mazer (University of Toronto, Toronto, CA) discusses the effect of empagliflozin on erythropoietin levels, iron stores and red blood cell morphology in patients with type 2 diabetes and coronary artery disease.

1.Why did you conduct this research?
2.How did you collect and analyse these data and what was the patient population?
3.What were your findings?
4.How should these data be interpreted and what can they teach us?

Filmed live on site at AHA 2019 by Radcliffe Cardiology.
Interviewer: Liam O'Neill / Videographer: Tom Green & Dominic Woodruff

See more videos here : https://www.radcliffecardiology.com/v...
RC Academy : https://www.radcliffecardiology.com/r...

radcliffecardiology.com is a dynamic, digitally-focused producer & publisher of Cardiovascular, Renal and Metabolic (CVRM) content for physicians worldwide. Radcliffe Cardiology also has a dedicated eLearning platform, RC Academy, which uses innovative platforms to host digital webinars, live case broadcasts and video roundtable discussions


When autoplay is enabled, a suggested video will automatically play next.

Up next

to add this to Watch Later

Add to

Loading playlists...